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Aims. Impaired fasting glucose (IFG) and diabetes are increasing in prevalence worldwide and lead to serious health problems. The
aim of this longitudinal study was to investigate the association between impaired fasting glucose or diabetes and mortality over a
10-year period in Australian women. Methods. This study included 1167 women (ages 20–94 yr) enrolled in the Geelong
Osteoporosis Study. Hazard ratios for all-cause mortality in diabetes, IFG, and normoglycaemia were calculated using a Cox
proportional hazards model. Results. Women with diabetes were older and had higher measures of adiposity, LDL cholesterol,
and triglycerides compared to the IFG and normoglycaemia groups (all p < 0 001). Mortality rate was greater in women with
diabetes compared to both the IFG and normoglycaemia groups (HR 1.8; 95% CI 1.3–2.7). Mortality was not diﬀerent in
women with IFG compared to those with normoglycaemia (HR 1.0; 95% CI 0.7–1.4). Conclusions. This study reports an
association between diabetes and all-cause mortality. However, no association was detected between IFG and all-cause mortality.
We also showed that mortality in Australian women with diabetes continues to be elevated and women with IFG are a valuable
target for prevention of premature mortality associated with diabetes.
1. Introduction
Impaired fasting glucose (IFG), a precursor of diabetes, is
increasing in prevalence and has been associated with
increased risk of cardiovascular disease [1–8]. IFG is deﬁned
by the American Diabetes Association (ADA) as elevated
fasting plasma glucose (FPG) and insulin resistance. IFG is
characterised as a FPG level between 5.5 and 6.9mmol/L
(100–125mg/dL) without antihyperglycaemic medication,
whereas diabetes is classiﬁed by FPG≥ 7.0mmol/L
(126mg/dL) [9]. We have recently reported that 33.8% of
Australian women have IFG and the likelihood of progres-
sing to diabetes over the ensuing decade was almost sixfold
greater if FPG≥ 6.1mmol/L [10]. Diabetes mellitus is a com-
plex disease that is also increasing in prevalence and can lead
to serious health complications, such as nephropathy [11],
retinopathy [12], neuropathy [13], stroke [11], coronary
artery disease [2], lower limb amputation [14], and early
mortality [15, 16]. It is estimated that 382 million people
worldwide have diabetes, and this number is expected to rise
to 592 million by 2035 [17]. In addition, it has been predicted
that diabetes is responsible for 4 million deaths worldwide in
2010 [15]. In Australia, diabetes is a growing disease with 280
new cases diagnosed every day [18].
Diabetes is associated with premature mortality [17], but
whether IFG is also associated with mortality risk is contro-
versial. Some studies have demonstrated a relationship
between IFG and mortality [1, 2]; whereas others have
reported no associations [19–21]. Therefore, the aim of this
study was to determine whether there is an association
between IFG or diabetes and mortality in Australian women
followed prospectively over a 10-year period.
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2. Methods
2.1. Study Design and Subjects. This study uses data from the
Geelong Osteoporosis Study (GOS), a population-based
study including participants residing in the Barwon Statisti-
cal Division. This region is situated in southeastern Australia
and has a large, stable population of approximately 280,000
and is largely representative of the Australian population,
making it ideal for epidemiological studies. The region also
contains residents with a range of cultural and socioeco-
nomic characteristics; however, most participants were of
European ancestry. A complete description of the method-
ology has been published elsewhere [22]. At baseline
(1993–1997), an age-stratiﬁed random sample of 1494
women aged 20–94 years was recruited from Common-
wealth electoral rolls, with a participation of 77.1%. We
excluded 326 women because we did not have a FPG level
or self-report of antihyperglycaemic medication or diabetes
status, leaving 1167 eligible women for this analysis. Those
who were excluded were older, shorter, and had lower
weight, lower lean mass, greater waist circumference,
higher serum triglycerides, lower serum HDL cholesterol,
higher systolic and diastolic blood pressure, with a lower
proportion of smokers, and lower mobility.
All-cause mortality was collated through the National
Death Index. The study was approved by the Barwon Health
Human Research Ethics Committee, and written informed
consent was obtained from all subjects.
2.2. Measurements. All exposure measurements were per-
formed at baseline. Weight and height were measured to
the nearest ±0.1 kg and ±0.1 cm, and body mass index
(BMI) was calculated as weight/height2 (kg/m2). Subjects
were categorised as obese if BMI≥ 30.0 kg/m2 [23]. Waist
circumference (minimal abdominal, between the ribs and
iliac crest) and hip circumference (maximal gluteal position)
were measured to the nearest ±0.5 cm. Waist-to-hip ratio
(WHR) and waist-to-height ratio (WHtR) were calculated
from these measurements. Whole-body scans were per-
formed using a dual-energy X-ray absorptiometry (DXA;
Lunar DPX-L; Lunar, Madison, WI). These scans also pro-
vided estimates of body fat mass (kg), percentage body fat
(%BF), and “lean”mass (kg), which includes the muscle, skin,
connective tissue, and the lean component of adipose tissue
(water and protein). We used a cut point of %BF> 30 for obe-
sity [24]. Blood pressure was measured in a sitting position
using an automated device (Takeda Medical UA-751).
Women were considered to be hypertensive if they had a
systolic blood pressure over 140mmHg and/or a diastolic
pressure above 90mmHg and/or use of antihypertensive
medication. Physical activity, alcohol consumption, current
smoking, and medication use were self-reported by a ques-
tionnaire. Women who reported undertaking regular physi-
cal activity were described as active; otherwise, they were
classiﬁed as inactive; high alcohol consumption was recog-
nised if alcohol was consumed at least several times a week.
Venous blood was collected at baseline after an over-
night fast. Fasting glucose was measured using an adapta-
tion of the hexokinase-glucose-6-phosphate dehydrogenase
method [25]. Blood samples were collected in sodium ﬂuoride
tubes by themajor pathology centre in the region, and glucose
assessment was completed soon after the blood collection.
There was no long-term storage of blood samples before mea-
surements. Diabetes was classiﬁed if FPG≥ 7.0mmol/L
(126mg/dL), self-reporting diabetes, and/or use of antihyper-
glycaemic agents (antihyperglycaemic medication use
referred to medications taken regularly and currently at base-
line). IFG was considered present if FPG level was between
5.5 and 6.9mmol/L (100–125mg/dL); according to the 2003
ADA diagnostic criteria [9]. Approximately, half (51.9%) of
diabetes caseswerediagnosedusingmultiple criteria including
FPG and self-report (13%), self-report and medication
(24.6%), and glucose, self-report, and medication use
(14.3%). Only 22% and 26% of diabetes cases were diagnosed
from glucose and self-report, respectively. Commercially
available kits and clinical chemistry analyser (Thermo Fisher
Scientiﬁc) were used to determine total cholesterol, high-
density lipoprotein cholesterol (HDL-C), low-density lipopro-
tein cholesterol (LDL-C), and triglycerides. The use of lipid-
lowering medications was investigated, but few women used
these agents (n = 51). In thesewomen, serum lipid resultswere
still outside the range recommended by the World Health
Organization (triglyceride< 2.0mmol/L; HDL level> 1.29m-
mol/L; LDL level≤ 3.5mmol/L) [26]. We also determined
whether the participants had metabolic syndrome based on
the International Diabetes Federation (IDF) criteria [27],
which included measurements of serum triglycerides, serum
HDL, waist circumference, and hypertension. FPG was
excluded in this analysis since our data were presented in
groups based on normoglycaemia, IFG, and diabetes. Suc-
cinctly, if a participant had a waist circumference> 80 cm
and had at least two of the following: (i) raised TG level:
≥1.7mmol/L, or speciﬁc treatment for this lipid abnormality;
(ii) reduced HDL cholesterol: <1.29mmol/L, or speciﬁc treat-
ment for this lipid abnormality; (iii) raised bloodpressure: sys-
tolicBP≥ 130mmHgordiastolicBP≥ 85mmHg,or treatment
of previously diagnosed hypertension; and then a participant
was considered to have metabolic syndrome.
2.3. Statistical Analyses. Kruskal-Wallis test for continuous
data was used to compare subject characteristics between
the three glycaemia groups (normoglycaemia, IFG, and dia-
betes). Categorical data were compared using the chi-
square test (or Fisher’s exact test). Overall survival rate per
glycaemia groups was calculated using Kaplan-Meier prod-
uct limit estimator. Survival curves were calculated accord-
ingly. Survival rates were compared between the three
groups with the use of a two-sided log-rank test. The hazard
ratios (HRs) for the diabetes group and IFG, as compared
with the normoglycaemia group, and corresponding 95%
conﬁdence intervals (95% CI) were estimated with the use
of a Cox proportional hazards model. We followed the par-
ticipants from their baseline appointment (1993–1997), until
31 of December 2012. We assessed a prespeciﬁed set of base-
line characteristics for their relevance as prognostic factors of
overall survival. We used a Cox proportional hazards model,
including diabetes status stratum, to perform bivariate
analysis of overall survival. Baseline characteristics
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signiﬁcant at a 0.1 level were then used to construct the mul-
tivariable model. We implemented a backward elimination
process with inclusion criteria of entry p value < 0.1 and exit
p value > 0.05 to identify the ﬁnal model. We explored two-
way interactions of dichotomised diabetes status (diabetes
versus nondiabetes) with all other signiﬁcant factors in the
ﬁnal model. Due to data sparseness interaction with 3-level
diabetes status was not possible. Estimated HR and two-
sided 95% CI and p values were calculated for relevant
prognostic factors. SPSS 22 was used for data analysis.
3. Results
At baseline, there were 696 (59.6%) women with normo-
glycaemia, 395 (33.8%) with IFG, and 76 (6.5%) with dia-
betes. The descriptive statistics for these women are
presented in Table 1.
Women with diabetes were older than those with
impaired fasting glucose and those with normoglycaemia.
In addition, those with diabetes had higher measures of adi-
posity than those with impaired fasting glucose or normogly-
caemia (p < 0 001). Measures of blood pressure were higher
in those with impaired fasting glucose and diabetes com-
pared with the normoglycaemic group. Serum triglycerides
and LDL cholesterol were higher in the IFG and diabetes
groups compared with the normoglycaemic group,
whereas HDL was lower in those with impaired fasting
glucose or diabetes. More women with IFG (39.0%) or
diabetes (68.4%) had metabolic syndrome than women
with normoglycaemia (21.6%). Unadjusted mortality was
higher in those with diabetes (n = 41; 53.3%) than those
with impaired fasting glucose (n = 89; 22.5%) and those
with normoglycaemia (n = 87; 12.5%).
Bivariate analyses showed the following baseline char-
acteristics to be candidate prognostic factors for overall
survival: diabetes status, age, serum LDL level, and smok-
ing (Table 2). Kaplan-Meier estimates of overall survival
by diabetes status are shown in Figure 1. Those with
Table 1: Descriptive characteristics of women at baseline stratiﬁed by glycaemic status (NFG=normal fasting glucose, IFG= impaired fasting
glucose, and diabetes). Data are shown as median (interquartile range) or n (%)∗.
NFG (n = 696) IFG (n = 395) Diabetes (n = 76) p value
Fasting plasma glucose (mmol/L)∗ 5.0 (4.8, 5.2) 5.7 (5.6, 5.9) 8.1 (6.6, 11.1) <0.001
Age (years) 42.1 (31.1, 42.1) 56.8 (44, 64.4) 65.2 (59.8, 75.3) <0.001
Weight (kg) 63.8 (57.3, 72.8) 69.5 (61.1, 80.8) 71.5 (60.8, 83.2) <0.001
Height (cm) 161.8 (157.9, 166.1) 160.5 (156.5, 165.3) 157.0 (153.0, 161.8) <0.001
BMI (kg/m2) 24.5 (22, 27.7) 26.9 (23.9, 31.4) 30.0 (25.6, 33.3) <0.001
BMI≥ 30 (kg/m2) 104 (14.9) 124 (31.4) 38 (49.4) <0.001
Body fat % 36.2 (30.6, 42.4) 41.0 (36.0, 45.7) 41.3 (37.1, 45.9) <0.001
Body fat %> 30% 534 (76.7) 363 (91.9) 66 (85.7) <0.001
Waist circumference (cm)∗ 79.0 (72.5, 87.4) 87.0 (78.6, 96.5) 96.4 (87.1, 104.6) <0.001
Hip circumference (cm)∗ 101.2 (96.2, 108.3) 106.3 (99.3, 106.3) 108.7 (98.9, 119.8) <0.001
Waist-to-hip ratio∗ 0.78 (0.74, 0.83) 0.82 (0.77, 0.86) 0.88 (0.84, 0.91) <0.001
Waist-to-height ratio∗ 0.49 (0.44, 0.55) 0.54 (0.49, 0.6) 0.62 (0.56, 0.67) <0.001
Systolic blood pressure (mmHg)∗ 114 (104, 128) 128 (115, 140) 141 (126.3, 163.5) <0.001
Diastolic blood pressure (mmHg)∗ 74 (66, 82) 79 (71, 86) 78.5 (73, 92.8) <0.001
Hypertension (%)∗¥ 184 (26.4) 181 (45.8) 62 (81.6) <0.001
Body fat mass (kg)∗ 23.0 (17.5, 30.3) 28.0 (22.1, 36.2) 29.5 (21, 37.1) <0.001
Lean mass (kg)∗ 38.4 (35.9, 41.3) 38.6 (35.4, 42.2) 38.7 (36.1, 41.9) 0.7
Serum triglycerides (mmol/L)∗ 0.94 (0.69, 1.36) 1.26 (0.89, 1.71) 2.01 (1.38, 2.42) <0.001
Serum HDL cholesterol (mmol/L)∗ 1.23 (1.02, 1.49) 1.20 (0.95, 1.45) 0.98 (0.84, 1.26) <0.001
Serum LDL cholesterol (mmol/L)∗ 2.71 (2.20, 3.36) 3.13 (2.55, 3.92) 2.96 (2.23, 3.44) <0.001
Current smoker 120 (17.1) 56 (14.2) 13 (17.1) 0.4
High alcohol consumption 115 (16.5) 89 (22.5) 6 (7.9) 0.003
Physically inactive 146 (21) 127 (32.2) 47 (61.8) <0.001
Metabolic syndrome∗† (%) 150 (21.6) 154 (39.0) 52 (68.4) <0.001
Mortality# 87 (12.5) 89 (22.5) 41 (53.9) <0.001
Person years of follow-up 42856.63 28333.58 6013.39 —
∗ indicates missing data: fasting plasma glucose and blood pressure n = 22; body fat and lean mass n = 8; percentage body fat n = 8; waist and hip
circumference, waist-to-hip ratio, and waist-to-height ratio n = 13; serum triglycerides n = 63; serum HDL cholesterol n = 61; serum LDL cholesterol n = 59;
metabolic syndrome n = 1. ¥ indicates that hypertensive (y/n) was considered if the participant had a systolic blood pressure > 140mmHg and/or a
diastolic pressure > 90mmHg and/or use of antihypertensive medication. † indicates metabolic syndrome excluding fasting plasma glucose. #
indicates unadjusted mortality.
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IFG had a similar overall survival to women with normo-
glycaemia over the follow-up period, but individuals with
diabetes had a shorter survival time compared to the other
two groups.
Table 3 also shows the ﬁnal adjusted model for the
analysis of diabetes status and mortality. After adjustment
for age and smoking status, the mortality rate for those
with IFG was not diﬀerent to the normoglycaemia group
(HR 1.0; 95% CI 0.74, 1.4), but those with diabetes showed
a higher mortality (HR 1.8; 95% CI 1.3, 2.7). Smoking was
independently associated with an increased mortality with
a hazard ratio of 2.0 (95% CI 1.3, 3.1). Additionally, age
at cohort entry was a signiﬁcant predictor of mortality,
with a hazard ratio per year of age of 0.93 (95% CI 0.91,
0.95). Model-adjusted cumulative survival curves by diabe-
tes status are shown in Figure 1.
Interactions between the variables in the model were
investigated. Only one interaction term was signiﬁcant: dia-
betes status and age (HR 0.964; 95% CI 0.934, 0.996;
p = 0 025). This interaction shows that with increasing age,
the risk of mortality associated with diabetes decreases.
4. Discussion
This longitudinal study determined the association between
IFG and diabetes and all-cause mortality over a 10-year
period in Australian women. Individuals with diabetes were
older and had higher indices of adiposity, serum triglycer-
ides, serum LDL cholesterol, blood pressure, alcohol con-
sumption, and more physical inactivity compared to the
other groups. The diabetes group also had lower serum
HDL cholesterol compared with the IFG and normoglycae-
mia groups. All-cause mortality was greater in those with dia-
betes, whereas we did not detect a diﬀerence in the mortality
risk for IFG compared to the normoglycaemia group. In
addition, smoking and age were independent predictors of
all-cause mortality in the ﬁnal adjusted model. We found that
older age entry at cohort was associated with a reduced all-
cause mortality, which may be explained by a “healthier par-
ticipant bias” [28]. Individuals in older age groups who were
alive and agreed to participate in our study at baseline were
likely to be healthier than those who declined to participate.
This may have created a bias for mortality in the older age
group. This study also showed that the association between
diabetes and mortality was independent of metabolic syn-
drome. This reinforces the importance a tight glycaemia
control and that elevated FPG in the diabetes range
increases the risk of mortality [29]. Recent data from the
United States [30] indicates that mortality attributed to
diabetes is up to three times higher than death certiﬁcate
data would suggest, with many cases of diabetes-related
mortality being classiﬁed as cardiovascular disease, renal
failure, or sepsis, leading to an underestimate of the con-
tribution of diabetes to all-cause mortality.
Table 2: Bivariate analyses and the ﬁnal multivariable cox model for diabetes and mortality. All variables were measured at baseline.
Factor
Bivariate
p value
Multivariate
p value
HR (95% CI) HR (95% CI)
Diabetes (yes) 1.61 (1.11, 2.35) 0.013 1.84 (1.26, 2.70) 0.002
Age (yr) 0.93 (0.91, 0.95) <0.001 0.93 (0.91, 0.95) <0.001
Weight (kg) 1.00 (0.99, 1.01) 0.621 — —
Height (cm) 1.02 (1.00, 1.05) 0.068 — —
BMI (kg/m2) 1.00 (0.97, 1.03) 0.824 — —
BMI> 30.0 kg/m2 1.17 (0.85, 1.63) 0.341 — —
Body fat %> 30% 1.31 (0.89, 1.93) 0.175 — —
Waist circumference (cm) 1.00 (0.99, 1.02) 0.784 — —
Hip circumference (cm) 1.00 (0.98, 1.01) 0.774 — —
Waist-to-hip-ratio 2.67 (0.28, 25.37) 0.394 — —
Waist-to-height ratio 0.76 (0.10, 5.67) 0.788 — —
Systolic blood pressure (mmHg) 1.00 (0.99, 1.01) 0.901 — —
Diastolic blood pressure (mmHg) 1.00 (0.99, 1.01) 0.422 — —
Hypertensive (y/n) 0.81 (0.62, 1.07) 0.136 — —
Body fat mass (kg) 1.00 (1.00, 1.00) 0.510 — —
Lean body mass (kg) 1.00 (1.00, 1.00) 0.068 — —
Serum triglycerides (mmol/L) 1.11 (0.93, 1.33) 0.234 — —
Serum HDL (mmol/L) 0.93 (0.64, 1.34) 0.689 — —
Serum LDL (<2.6mmol/L) 0.74 (0.54, 1.01) 0.061 0.79 (0.58, 1.10) 0.160
Smoking 2.56 (1.64, 4.00) <0.001 1.91 (1.21, 3.02) 0.006
High alcohol consumption 0.83 (0.59, 1.17) 0.278 — —
Low mobility∗ 0.92 (0.69, 1.22) 0.552 — —
Metabolic syndrome 0.89 (0.68, 1.17) 0.413 — —
∗ indicates that mobility was assessed with an ordinal scale as well (from 1 to 7), but p = 0 774.
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There have been many studies investigating the associa-
tion of IFG with mortality which have been collated in a
meta-analysis which included 26 articles [31]. Using ADA
criteria for IFG, the meta-analysis reported that IFG was not
associated with an increased risk of all-cause mortality, com-
pared to normoglycaemia (RR 1.07 95%CI 0.92–1.26), similar
to our results. Other additional studies did not ﬁnd any
association between IFG and mortality risk [19–21]. Among
US participants aged 52–75 years followed for 6.3 years, there
was no association between IFG (ADA criteria) and all-cause
mortality (HR 0.93; 95% CI 0.70–1.24) [19]. Two additional
US studies with follow-up periods of 7.5 [1] and 13 years [21]
and a Finnish studywith 13 years of follow-up did not demon-
strate an association between IFG and all-causemortality [20].
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Figure 1: Unadjusted (a) andmodel adjusted (b) cumulative survival functions for fasting glucose status versus age at death (x-axis). Adjusted
model includes fasting plasma glucose, age at cohort entry, and smoking status.
Table 3: Multivariable model for evaluating diabetes status and risk of mortality.
Factor p value HR Lower 95% CI Upper 95% CI Median survival (95% CI)∗
Glycaemia status 0.003 — — — 90.7 (89.7, 91.8)
Normoglycaemia — — — — 90.0 (87.3, 92.7)
Impaired fasting glucose — 1.002 0.743 1.351 91.7 (89.4, 94.1)
Diabetes — 1.843 1.256 2.703 86.8 (83.4, 91.6)
Smoking (yes) 0.003 1.962 1.251 3.077 82.5 (80.7, 84.3)
Age at cohort entry (years) <0.001 0.932 0.912 0.953 —
∗Overall median survival age (years).
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Other studies have reported an association between IFG
and mortality. For example, a prospective study of 2641
middle-aged men from Eastern Finland followed over 19
years showed that IFG was a risk factor for all-cause mortal-
ity (relative risk (RR) 1.31 (95% CI) (1.11–2.87)) [2]. Our
study had a similar follow-up time; however, we did not show
an association between IFG and all-cause mortality. One rea-
son for this may be due to sample size; the Finnish study had
more participants who could have their FPG followed.
Although that study did not report the RR of FPG for all-
cause mortality, they did show that there was a 10% increase
in risk of sudden cardiac death with a 1.0mmol/L increase in
FPG (RR 1.10 (95% CI) 1.04–1.20, p = 0 001). Other impor-
tant diﬀerences may be the longer duration of the Finnish
study compared to our study, and that we included only
women, whereas the Finnish study included only men.
By contrast, many studies have shown a clear association
between diabetes and all-cause mortality. A study including
data from 22 European cohorts investigated the association
between diabetes (FPG≥ 7.0mmol/L) and all-cause mortal-
ity. Diabetes was associated with an increase in all-cause
mortality across an 11-year follow-up; data combined from
all 22 cohorts resulted in a HR of 1.6 (95% CI 1.4–1.8),
similar to our estimate (HR 1.8, 95% CI 1.26–2.7) [32].
Some studies have investigated all-cause mortality in type
2 diabetes patients and consistently reported that individ-
uals with diabetes have a higher risk of all-cause mortality,
similar to our results [33, 34]. Saydah et al. have also esti-
mated that diabetes is responsible for 3.6% of all deaths in
Americans adults [35].
Diabetes often develops in the context of a westernised
lifestyle, poor diet, and low-physical activity, leading to
increased obesity levels and, eventually, beta-cell failure and
diabetes. Additionally, systemic inﬂammation, hypertension,
and dyslipidaemia occur simultaneously which leads to car-
diovascular disease and increased risk of mortality [29]. In
our study, we observed many of these lifestyle and physiolog-
ical risk factors including lower physical activity and higher
levels of obesity in women with diabetes compared to both
IFG and normoglycaemia. Women with diabetes also had
higher levels of hypertension and dyslipidaemia; 51.5%,
77.9%, and 25.0% had triglycerides, HDL and LDL, respec-
tively, outside the recommended range.
Our study has some strengths and limitations. A major
strength is that the participants were randomly selected and
thus are representative of the general population. Our study
also included a wide age range with considerable follow-up
time. We also used a robust method for diabetes diagnosis,
which combined a FPG measurement, self-report, and med-
ication use. The study also utilised whole-body densitometry
for the assessment of body fat mass and lean mass which
more accurately assesses body composition estimated from
anthropometric measurements [36]. Another strength of this
study was complete ascertainment of mortality that was iden-
tiﬁed through the National Death Index. However, we
acknowledge that there are some limitations to our study.
The majority of the participants were white females, and
our results may not be generalisable to other populations.
The women who participated at baseline but who were
excluded from the study due to insuﬃcient information to
classify diabetes status diﬀered from those who were included
in the study on factors that might have predisposed them to
impaired fasting glucose or diabetes. Another limitation of
the study was that diabetes status categorised based on a sin-
gle FPG, whereas international guidelines require an elevated
fasting glucose on at least two occasions. Furthermore, we did
not have information on speciﬁc causes of mortality. Finally,
we did rely on some self-reported data such as medication
use, smoking, alcohol consumption, and physical activity,
which may not be accurate, but it is important to note that
most of our analyses were based on biochemical and clinical
measurements as well as mortality data from the National
Death Index.
5. Conclusions
In this study, we report that diabetes was associated with a
higher risk of all-cause mortality; however, there was no dif-
ference detected in risk between women with IFG and
women with normoglycaemia over 10 years of follow-up.
We also showed that mortality in Australian women with
diabetes continues to be elevated, indicating that secondary
prevention measures have not been eﬀective at reducing pre-
mature mortality in this group. Given that we did not ﬁnd an
association between IFG and all-cause mortality, women
with IFG are a valuable target for prevention of premature
mortality associated with diabetes.
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